Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 16
States / cities: Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more

Conditions: Chronic Obstructive Pulmonary Disease, Depression
Interventions: Advair diskus; Drug
Lead sponsor: Valley Medical Research; Other
Eligibility: 18 Years to 94 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Brooksville, Florida • Centerville, Ohio

Conditions: Asthma, Candidiasis, Oral, Voice Disorders
Interventions: fluticasone/salmeterol DISKUS 250/50; Drug
Lead sponsor: Allergy & Asthma Medical Group & Research Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: Asthma
Interventions: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 58
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Asthma
Interventions: QVAR, Advair, Servent Diskus; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 58
States / cities: Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more

Conditions: Asthma
Interventions: Fluticasone/Salmeterol Diskus, Fluticasone Diskus; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Asthma
Interventions: fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more

Conditions: Asthma
Interventions: Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more

Conditions: Asthma
Interventions: fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more

Conditions: Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions: salmeterol-fluticasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 28
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 16 more

Conditions: Asthma
Interventions: Xolair injections; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Search by objective public record fields.

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The Effect on Depressive Symptoms in ECF Residents With COPD

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Environmental Control as Add-on Therapy in Childhood Asthma

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Non-invasive Measures of Distal Lung Disease in Asthmatics

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Long-acting Beta Agonist Step Down Study

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

Best African American Response to Asthma Drugs

Non-invasive Measures of Effects of Xolair in Asthma

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)